Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912178 | 0.94 | MAPT (0.53) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL15043478 | 0.84 | POLB (0.51) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL15043471 | 0.81 | POLB (0.48) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL21755744 | 0.78 | POLB (0.52) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL9910991 | 0.78 | MAPT (0.45) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL24120919 | 0.75 | TP53 (0.70) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL9912167 | 0.74 | LMNA (0.60) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL24121153 | 0.74 | RXFP1 (0.69) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL24120915 | 0.74 | TP53 (0.68) | TP53MAPTPOLBRXFP1LMNA | |
| SCHEMBL24121118 | 0.72 | TP53 (0.65) | TP53MAPTPOLBRXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | TP53 817/4885MAPT 4217/4885POLB 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.